We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Monoclonal Antibody Treatment Blocks Lymphoma Progression in Mouse Model

By LabMedica International staff writers
Posted on 16 Aug 2016
Print article
Image: Blocking JAM-C on lymphoma cells inhibits their migration through vessel walls (Photo courtesy of the Université de Genève).
Image: Blocking JAM-C on lymphoma cells inhibits their migration through vessel walls (Photo courtesy of the Université de Genève).
Immunotherapy based on monoclonal antibodies that specifically bind to the surface protein junctional adhesion molecule (JAM)-C, which is expressed by a variety of different cell types, including human B lymphocytes and some B-cell lymphoma subtypes, blocked progression of lymphoma in a mouse xenograft model of mantle cell lymphoma.

Previous studies had shown that treatment with anti-JAM-C polyclonal antibodies reduced homing of human B cells to lymphoid organs in a NOD/SCID mouse model. In the present study, which was published in the June 2, 2016, online edition of the Journal of Leukocyte Biology, the role of JAM-C in the engraftment of human lymphoma B cells in mice was investigated.

Investigators at Université de Genève (Switzerland) worked with the "H225" monoclonal antibody that had been designed to bind solely to JAM-C. They found that administration H225 reduced tumor growth of JAM-C+ MCL cells in bone marrow, spleen, liver, and lymph nodes of mice. Treatment with anti-JAM-C antibodies significantly reduced the proliferation of JAM-C-expressing lymphoma B cells. Moreover, the binding of anti-JAM-C antibodies inhibited the phosphorylation of ERK1/2, without affecting other signaling pathways.

"Since they cannot survive in the blood for long, these malignant cells are compelled to find a more accommodating environment - such as the lymphatic system - where they can proliferate. We decided to focus on this Achilles heel by containing them in the blood so as to prevent any resulting harm," said senior author Dr. Thomas Matthes, professor of medicine at Université de Genève.

In other words, masking JAM-C expression with H225 prevented more than 50% of lymphoma cells from migrating out of blood vessels and into the lymphoid organs where they could have developed into lymphoma tumors. "This is not its only effect," said Dr. Matthes, "H225 also significantly limited cell proliferation, even when tumor cells had already settled in the lymphatic system. In our mice, we observed the nearly-complete disappearance of already-present tumor cells in the organs."

Related Links:
Université de Genève

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.